Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS. — CFSMEATLAS
Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS.
This review examines why people with ME/CFS may develop heart problems earlier than others. The researchers found that ME/CFS involves abnormal inflammation and oxidative stress (damage from harmful molecules in the body), along with low levels of protective antioxidants. These biological changes can damage the heart and blood vessels, potentially explaining why some ME/CFS patients experience heart failure at much younger ages than the general population.
Why It Matters
This study addresses a serious gap in ME/CFS research: the observation that patients die from heart failure 25 years earlier than the general population. Understanding the biological mechanisms behind this increased cardiovascular risk could inform preventive screening, therapeutic interventions, and help validate ME/CFS as a serious medical condition with measurable physiological consequences.
Observed Findings
ME/CFS patients dying from heart failure had a mean age of 58.7 years, compared to 83.1 years in the general US population.
Chronic low-grade inflammation in ME/CFS involves elevated nuclear factor kappa B (NF-κB) and COX-2 with increased tumor necrosis factor alpha (TNF-α).
ME/CFS patients show increased oxidative and nitrosative stress with elevated peroxide levels and phospholipid peroxidation.
Specific antioxidant deficiencies documented in ME/CFS include coenzyme Q10, zinc, and dehydroepiandrosterone-sulfate (DHEA-S).
Dysregulation in multiple IO&NS pathways provides plausible explanations for the increased cardiovascular risk and premature mortality observed in ME/CFS.
ME/CFS should be recognized as a multisystemic metabolic-inflammatory disorder with serious systemic consequences beyond fatigue.
These aberrations in IO&NS pathways may be therapeutic targets for reducing cardiovascular complications in ME/CFS patients.
Remaining Questions
Do these IO&NS pathway abnormalities directly cause cardiovascular disease in ME/CFS, or are they markers of underlying pathology?
What This Study Does Not Prove
This mechanistic review does not prove that any single IO&NS pathway directly causes cardiovascular disease in ME/CFS patients, nor does it establish causation rather than association. The study does not present new experimental data and cannot rule out other contributing factors to premature cardiovascular mortality, such as reduced physical activity, medication effects, or healthcare disparities.